Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
On June 16, 2021, Selecta Biosciences (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will provide a corporate update and engage in one-on-one investor meetings at the Raymond James Human Health Innovation Conference, scheduled for June 21-23, 2021. The presentation will take place on June 23 at 12:00 p.m. ET, available via the conference portal. Selecta leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, targeting autoimmune diseases, enzyme, and gene therapies. More information can be found on Selecta's official website.
- None.
- None.
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Raymond James Human Health Innovation Conference to be held virtually, June 21-23, 2021.
The presentation on Wednesday, June 23 at 12:00 p.m. ET will be available through the Raymond James conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
What is the date of Selecta Biosciences' presentation at the Raymond James Human Health Innovation Conference?
Who is providing the corporate update for Selecta Biosciences at the conference?
How can investors access the Selecta Biosciences presentation?
What is the main focus of Selecta Biosciences' ImmTOR™ platform?
What types of therapies is Selecta Biosciences developing?
